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Abstract: Purpose: Evaluation of contrast sensitivity in patients with beta-thalassemia major and sickle cell disease which 
undergo regular transfusions and chelation therapy with desferrioxamine (DFX). 
Materials and Methods: We studied contrast sensitivity in 48 eyes (24 patients) with beta-thalassemia major (group A) 
and in 42 eyes (21 patients) with sickle cell disease (group B), compared to 60 eyes of 30 healthy individuals (control 
group). Contrast sensitivity was measured using B-VAT II-SG Mentor Video Aquity Tester. 
Results: We found no statistically significant difference between group A and group B in any spatial frequency, while we 
found statistically significant differences between group B and control group in all spatial frequencies studied. Between 
group A and control group we found statistically significant differences in spatial frequencies of 2.3, and 6 cyc/deg. 
Conclusion: DFX causes retinal alterations that may explain reductions in contrast sensitivity function and justifies regular 
evaluations that may allow early detection of visual function deterioration. 
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INTRODUCTION 
  Blood transfusion on a continual basis is the primary if 
not the only treatment in various refractory and aplastic 
anemias most notably beta-thalassemia major (BTM) and 
sickle cell disease (SCD) [1]. Although this can prevent 
death from anemia in infancy and permit normal growth and 
development during childhood, blood transfusions are 
responsible for accumulation of toxic amounts of iron in 
tissues which eventually leads to organ failure [2]. 
  Desferrioxamine (diethylenetriamine penta-acetic acid) 
(DFX), an iron chelating agent is used extensively to 
maintain iron balance, however itself may cause sideffects. 
Ocular toxicity of DFX first came to light when four patients 
with BTM were treated with a high intravenous dose to 
counter the effects of transfusion induced iron overload [3]. 
Two patients developed night blindness and visual field 
defects which improved upon withdrawal of the drug. In the 
past years studies have associated high doses of DFX with 
lens opacities, visual loss, loss of color vision, night 
blindness, visual field defects, dyschromatopsia [1, 4]. 
  Considering the above reports, we conducted an 
ophthalmologic evaluation of patients with BTM and SCD 
undergoing regular chelation therapy with DFO, using   
 
 
*Address correspondence to this author at the Epirus Vision Center, 
Panepistimiou Avenue, Ioannina, 45110, Greece; Tel: +302651067689; Fax: 
+302651067889; E-mail: gorezis@hotmail.com 
contrast sensitivity to test their visual function. Recent 
literature regards contrast sensitivity as a more sensitive 
method than Snellen visual acuity testing [5, 6]. Impaired 
contrast sensitivity in the presence of normal visual acuity 
has also been related with various retinal and optic nerve 
diseases [7-10]. Therefore, this method seems to be better 
indicated as a primary screening test for detecting early 
functional visual loss in patients with BTM and SCD that 
present with normal visual acuity in the Snellen chart. 
MATERIALS AND METHODOLOGY 
  We studied a group of 48 eyes (24 patients) with BTM 
(group A) and 42 eyes (21 patients) with SCD (group B) 
against a control group of 60 eyes of 30 healthy individuals 
(control group). The study was conducted over a period of 
three monthes. Patients were followed at the Pediatrics 
Department of the University Hospital of Ioannina; they 
were all regularly transfused and treated by subcutaneous 
infusions of DFX. Specifically, in BTM the transfusions 
were performed depending on the gravity of the case every 1 
to 3 weeks. For sickle cell anemia transfusions were 
performed durind aplastic crisis, splenic pooling and CNS 
episodes. Inclusion criteria were best corrected visual acuity 
of 20/20 or better and no history of any ocular disease. 
Control subjects were matched for age and sex with patients 
and were questioned for any history of ocular disease or 
medication that could affect contrast sensitivity evaluation. 
All participants underwent an ophthalmic evaluation that 
consisted of Snellen visual acuity evaluation, contrast 40    The Open Ophthalmology Journal, 2010, Volume 4  Spyridon et al. 
sensitivity evaluation, slit lamp microscopy and dilated pupil 
fundus examination. Fluroscein angiography was performed 
in all patients. Both eyes were studied separately. 
  The Mentor B-VAT II Video Acuity Tester (Mentor 
O&O Inc., MA) generates sine wave gratings with spatial 
frequencies of 1.5, 3, 6, 12, and 18 cyc/deg and contrast 
levels of up to 98% on a computer processor module, which 
are displayed on a cathode ray tube monitor. Threshold was 
determined using a three-alternative forced-choice staircase 
procedure with a converging performance level of 70% in 
which patients were required to identify the orientation of 
gratings, which lie either vertical or obliquely oriented to the 
right or left by 15°. Stimulus contrast was reduced after two 
correct responses and increased after one incorrect response. 
Threshold was calculated as the mean of the last eight 
contrast reversals. The monitor was viewed from 3 m in a 
darkened room and had a mean luminance of 85 cd/m2. 
  Statistical analysis was performed with ANOVA in SPSS 
v12. 
RESULTS 
  A total of 150 eyes were included in our study. Forty-
eight of them belonged to BTM patients, 42 to SCD patients 
and 60 eyes served as controls. Groups were matched for 
age, sex and refractive data. Mean age in years was 
31,09±6,54 for BTM patients (22 to 45), 27,75±5,49 for 
SCD patients (20 to 40) and 27,57±5,06 for control group 
(20 to 40). Male to female ratio can be seen in Table 1. The 
dose of DFX administrated to the patients was 
50mgr/kgr/day four to five days a week. Mean disease 
duration was 15± 2,3 years in BTM and 13±2,45 in SCD 
patients. Mean treatment duration was 12, 16±2, 44. 
  Slit lamp examination did not reveal any findings in any 
case. No macular edema or other pigmentary changes on the 
macula were observed in any of the cases. One patient with 
BTM was excluded due to angiotic streaks and 1 patient with 
SCD was excluded due to retinal epithelial changes. 
  There was no statistically significant difference between 
groups regarding Snellen visual acuity. 
  We found no statistically significant difference between 
group A and group B in any spatial frequency that we 
studied, while statistically significant differences were 
demonstrated between group B and control group in all 
spatial frequencies studied (2,3, 6, 12, 18 cyc/deg). CSF 
values in all three groups are presented in Table 2. Between 
group A and control group we found statistically significant 
differences in spatial frequencies of 2, 3, and 6 cyc/deg. 
 
 
Table 2.  CSF Values in the All Three Groups 
 
CSF Values (cyg/deg)  Group  Log Units 
SF 1.50 D 
control 
BTM 
SCD 
2.21 ±0.77 
1.34±0.40 
1.51±0.53 
SF 1.50 S 
control 
BTM 
SCD 
1.95±0.53 
1.41±0.61 
1.51±0.53 
SF 3 D 
control 
BTM 
SCD 
1.81±0.44 
1.19±0.31 
1.05±0.53 
SF 3S 
control 
BTM 
SCD 
1.72±0.54 
1.07±0.05 
1.05±0.23 
SF 6 D 
control 
BTM 
SCD 
1.84±0.53 
1.27±0.47 
1.41±0.47 
SF 6 S 
control 
BTM 
SCD 
1.78±0.61 
1.36±0.89 
1.41±0.47 
SF 12 D 
control 
BTM 
SCD 
3.21±1.08 
2.63±1.14 
2.44±0.98 
SF12 S 
control 
BTM 
SCD 
3.06±1.16 
2.44±0.82 
2.44±0.98 
SF18 D 
control 
BTM 
SCD 
5.51±1.63 
5.03±2.05 
4.47±2.39 
SF 18 S 
control 
BTM 
SCD 
6.19±2.79 
6.77±3.32 
6.91±3.26 
 
DISCUSSION 
  Mitchell [11] shows that contrast sensitivity (CS) can 
better discriminate ophthalmic disease in certain populations 
compared to Snellen visual acuity. Woods [6] further found 
that CS sensitivity was more efficient in measuring visual 
acuity than Snellen visual acuity method as a screening 
technique, too. Results in our study confirm that contrast   
 
Table 1.  Age, Gender, Therapy Duration and Blood Ferritin Levels in Groups Under Study 
 
  BTM SCD  Control  Group 
Age (years)  31,09±6,54 27,75±5,49  27,57±5,06 
Male/Female  14/9 15/5  20/10 
DFX treatment duration (years)  12,48±2,83 11,9±2,25  - 
Ferritin levels (ng/mL)  2036,17±2520,30 1988,95±2974,15  194,1±78,6 Contrast Sensitivity in Patients with Beta-Thalassemia Major  The Open Ophthalmology Journal, 2010, Volume 4    41 
sensitivity can be significantly impaired in patients with 
BTM and patients with SCD compared to healthy 
individuals, while Snellen visual aquity seems unaffected. 
This is in accordance with previous studies reflecting the fact 
that early alterations in retinal physiology cause slight and 
difficult to detect changes in the way neuroreceptors 
perceive stimuli. 
  DFX administration has been reported to affect the eye in 
many ways. Correlations have been made with the age of 
patients or the dosage of DFX. Side effects include lens 
opacities, changes in the retinal pigment epithelium, 
tortuosity of retinal vessels, dilation and sheathing of retinal 
vessels. Few studies however assess functional visual loss 
which precedes the appearance of visible ocular changes 
  Contrast sensitivity is reduced compared to the control 
group for all spatial frequencies under study in patients with 
sickle cell disease and in low and medium spatial 
frequencies in patients with beta-thalassemia major. 
Important factor that may be responsible for our findings is 
desferioxamine’s toxic effect. Toxic retinopathy is one of the 
complications associated
  with deferoxamine, in which 
different manifestations including
  pigmentary retinopathy, 
bull’s eye maculopathy, and vitelliform
  maculopathy have 
been described [12]. Whether or not certain changes 
observed in the retinal pigment epithelium (RPE) cells and in 
Bruch’s membrane are in part due to ocular siderosis, is 
difficult to determine. RPE changes following high doses of 
DFX have been microscopically confirmed through 
histochemical studies. Loss of microvilli from the apical 
surface, patchy degeneration, vacuolation of the cytoplasm, 
swelling and calcification of mitochondria as well as 
disorganization of the plasma membrane [4] were described. 
  Recovery when DFX is stopped and pathological reports 
that do not reveal iron deposition in RPE cells support 
toxicity of the drug. The mechanism is not completely clear. 
DFX as a chelating agent binds not only to iron but copper 
and zinc, as well, both of which are important components of 
retinal pigment epithelium. De Virgilis et al. [13] reported 
transient and permanent electroretinogram abnormalities, 
related to zinc and copper or iron depletion, in BTM patients 
receiving high doses of intravenous DFX. 
  In pediatric groups examined during the last years, DFO-
treated patients presented rare and mild findings of ocular 
toxicity [14], and furthermore deferoxamine at doses lower 
than 50 mg/kg/d was safe for the eyes and slightly toxic to 
the ears [15]. 
  Under this perspective, contrast sensitivity evaluation is 
important in patients who receive constant, large doses of 
desferioxamine, in order to detect early changes in visual 
acuity. However it must be stressed that taking into account 
that the consequence of no DFX treatment is early death, the 
risk-benefit ratio of chelation therapy remains extremely 
low. 
  Contrast sensitivity is reduced compared to the control 
group for all spatial frequencies under study in patients with 
sickle cell disease and in low and medium spatial 
frequencies in patients with beta-thalassemia major. 
Important factor that may be responsible for our findings is 
deferoxamine’s toxic effect. 
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ABBREVIATIONS 
DFX =  Desferrioxamine 
BTM =  Beta-thalassemia  major 
SCD  =  Sickle cell disease 
CNS =  Central  nervous  system 
REFERENCES 
[1]  Zafeiriou DI, Kousi AA, Tsantali CT, et al. Neurophysiologic 
evaluation of long-term desferrioxamine therapy in beta-
thalassemia patients. Pediatr Neurol 1998; 18: 420-4. 
[2]  Graziano JH, Markenson A, Miller DR, et al. Chelation therapy in 
beta-thalassemia major. Intravenous and subcutaneous 
deferoxamine. J Pediatr 1978; 92: 648-2. 
[3]  Davies SC, Marcus RE, Hungerford JL, Miller MH, Arden GB, 
Huehns ER. Ocular toxicity of high-dose intravenous 
desferrioxamine. Lancet 1983; 2: 181-4. 
[4]  Rahi AHS, Hungerford JL, Ahmed AI. Ocular toxicity of 
desferrioxamine: light microscopic, histochemical and 
ultrastructural findings. Br J Ophthalmol 1986; 70: 373-81. 
[5]  Regan D, Neima D. Low-contrast letter charts as a test of visual 
function. Ophthalmology 1983; 90: 1192-200. 
[6]  Woods RL, Tregear SJ, Mitchell RA. Screening for ophthalmic 
disease in older subjects using visual acuity and contrast sensitivity. 
Ophthalmology 1998; 105: 2318-26. 
[7]  Fiorentini A, Lamberto M. Spatial contrast sensitivity of myopic 
subjects. Vision Res 1976; 16: 437-8. 
[8]  Maraini G, Rosmini F, Graziosi P, et al. Influence of type and 
severity of pure forms of age-related cataract on visual acuity and 
contrast sensitivity. Invest Ophthalmol Vis Sci 1994; 35: 262-7. 
[9]  Mela EK, Gartaganis SP, Koliopoulos JX. Contrast sensitivity 
function after cataract extraction and intraocular lens implantation. 
Doc Ophthalmol 1996; 92: 79-81. 
[10]  Lindstrom R. Food and Drug Administration study update. One-
year results from 671 patients with the 3M multifocal intraocular 
lens. Ophthalmology 1993; 100: 91-7. 
[11]  Mitchell RA. Contrast sensitivity in elderly subjects with a 
diagnosed ocular disease. Optom Vis Sci 1993; 70: 102-6. 
[12]  Lai TY, Lee GK, Chan WM, Lam DS. Rapid development of 
severe toxic retinopathy associated with continuous intravenous 
deferoxamine infusion. Br J Ophthalmol 2006; 90: 243-4. 
[13]  De Virgiliis S, Congia M, Frau F, et al. Deferoxamine-induced 
growth retardation in patients with thalassemia major. J Pediatr 
1988; 113: 661-9. 
[14]  Baath JS, Lam WC, Kirby M, Chun A. Deferoxamine-related 
ocular toxicity: incidence and outcome in a pediatric population. 
Retina 2008; 28: 894-9. 
[15]  Chen SH, Liang DC, Lin HC, Cheng SY, Chen LJ, Liu HC. 
Auditory and visual toxicity during deferoxamine therapy in 
transfusion-dependent patients. J Pediatr Hematol Oncol 2005; 27: 
651-3.
 
 
Received: January 14, 2010  Revised: January 22, 2010  Accepted: March 25, 2010 
 
© Spyridon et al.; Licensee Bentham Open. 
 
This is an open access article licensed under the terms of the Creative Commons Attribution Non-Commercial License (http: //creativecommons.org/licenses/by- 
nc/3.0/) which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited. 